{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:35:09Z","timestamp":1791477309925,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11914-017-0365-0","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T06:36:56Z","timestamp":1493361416000},"page":"198-206","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Treatment of Pediatric Chronic Kidney Disease-Mineral and Bone Disorder"],"prefix":"10.1007","volume":"15","author":[{"given":"Mark R.","family":"Hanudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"issue":"11","key":"365_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Dr\u00fceke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69(11):1945\u201353.","journal-title":"Kidney Int"},{"key":"365_CR2","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1\u2013130."},{"issue":"6","key":"365_CR3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00467-006-0040-7","volume":"21","author":"MG Seikaly","year":"2006","unstructured":"Seikaly MG, Salhab N, Gipson D, Yiu V, Stablein D. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol. 2006;21(6):793\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"365_CR4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1681\/ASN.2015020152","volume":"27","author":"MR Denburg","year":"2016","unstructured":"Denburg MR, Kumar J, Jemielita T, Brooks ER, Skversky A, Portale AA, Salusky IB, Warady BA, Furth SL, Leonard MB. Fracture burden and risk factors in childhood CKD: results from the CKiD cohort study. J Am Soc Nephrol. 2016;27(2):543\u201350.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"365_CR5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/adc.50.7.545","volume":"50","author":"O Mehls","year":"1975","unstructured":"Mehls O, Ritz E, Krempien B, Gilli G, Link K, Willich E, Sch\u00e4rer K. Slipped epiphyses in renal osteodystrophy. Arch Dis Child. 1975;50(7):545\u201354.","journal-title":"Arch Dis Child"},{"issue":"10","key":"365_CR6","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.2215\/CJN.01330210","volume":"5","author":"SA Bakkaloglu","year":"2010","unstructured":"Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB. Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol. 2010;5(10):1860\u20136.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"365_CR7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, J\u00fcppner H, Salusky IB. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011;79(1):112\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"365_CR8","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2215\/CJN.05940611","volume":"7","author":"K Wesseling-Perry","year":"2012","unstructured":"Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, J\u00fcppner H, Salusky IB. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol. 2012;7(1):146\u201352.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"365_CR9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00467-009-1248-0","volume":"25","author":"LT Weber","year":"2010","unstructured":"Weber LT, Mehls O. Limitations of dual x-ray absorptiometry in children with chronic kidney disease. Pediatr Nephrol. 2010;25(1):3\u20135.","journal-title":"Pediatr Nephrol"},{"issue":"8","key":"365_CR10","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1093\/ndt\/gfs299","volume":"27","author":"J Bacchetta","year":"2012","unstructured":"Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K. The consequences of chronic kidney disease on bone metabolism and growth in children. Nephrol Dial Transplant. 2012;27(8):3063\u201371.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"365_CR11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jocd.2014.01.007","volume":"17","author":"CM Gordon","year":"2014","unstructured":"Gordon CM, Leonard MB, Zemel BS, International Society for Clinical Densitometry. 2013 Pediatric Position Development Conference: executive summary and reflections. J Clin Densitom. 2014;17(2):219\u201324.","journal-title":"J Clin Densitom"},{"issue":"2","key":"365_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0720-048X(97)00093-4","volume":"26","author":"V Gilsanz","year":"1998","unstructured":"Gilsanz V. Bone density in children: a review of the available techniques and indications. Eur J Radiol. 1998;26(2):177\u201382.","journal-title":"Eur J Radiol"},{"issue":"6","key":"365_CR13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00467-002-1041-9","volume":"18","author":"EM Lima","year":"2003","unstructured":"Lima EM, Goodman WG, Kuizon BD, Gales B, Emerick A, Goldin J, Salusky IB. Bone density measurements in pediatric patients with renal osteodystrophy. Pediatr Nephrol. 2003;18(6):554\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"5","key":"365_CR14","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1210\/jc.2012-4188","volume":"98","author":"MR Denburg","year":"2013","unstructured":"Denburg MR, Tsampalieros AK, de Boer IH, Shults J, Kalkwarf HJ, Zemel BS, Foerster D, Stokes D, Leonard MB. Mineral metabolism and cortical volumetric bone mineral density in childhood chronic kidney disease. J Clin Endocrinol Metab. 2013;98(5):1930\u20138.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"365_CR15","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00774-014-0590-x","volume":"33","author":"C Gkogka","year":"2015","unstructured":"Gkogka C, Christoforidis A, Printza N, Kollios K, Kazantzidou E, Papachristou F. Longitudinal assessment of bone quality in pediatric patients with chronic kidney disease in relation to treatment modality. J Bone Miner Metab. 2015;33(3):303\u201310.","journal-title":"J Bone Miner Metab"},{"issue":"12","key":"365_CR16","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"\u2022 Isakova T, Wahl P, Vargas GS, Guti\u00e9rrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370\u20138. This study demonstrates that elevated FGF23 levels are the first observed biochemical abnormality in adult CKD-MBD","journal-title":"Kidney Int"},{"issue":"2","key":"365_CR17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2215\/CJN.05840513","volume":"9","author":"AA Portale","year":"2014","unstructured":"\u2022 Portale AA, Wolf M, J\u00fcppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB. Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol. 2014;9(2):344\u201353. This study demonstrates that elevated FGF23 levels are the first observed biochemical abnormality in pediatric CKD-MBD","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"365_CR18","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1074\/jbc.M408903200","volume":"280","author":"H Saito","year":"2005","unstructured":"Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem. 2005;280(4):2543\u20139.","journal-title":"J Biol Chem"},{"issue":"8","key":"365_CR19","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2006-0021","volume":"91","author":"DM Antoniucci","year":"2006","unstructured":"Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91(8):3144\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"365_CR20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1172\/JCI111365","volume":"73","author":"AA Portale","year":"1984","unstructured":"Portale AA, Booth BE, Halloran BP, Morris RC Jr. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest. 1984;73(6):1580\u20139.","journal-title":"J Clin Invest"},{"issue":"4","key":"365_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1172\/JCI200419081","volume":"113","author":"T Shimada","year":"2004","unstructured":"Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004;113(4):561\u20138.","journal-title":"J Clin Invest"},{"issue":"11","key":"365_CR22","doi-asserted-by":"crossref","first-page":"9843","DOI":"10.1074\/jbc.M210490200","volume":"278","author":"XY Bai","year":"2003","unstructured":"Bai XY, Miao D, Goltzman D, Karaplis AC. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem. 2003;278(11):9843\u20139.","journal-title":"J Biol Chem"},{"issue":"6","key":"365_CR23","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1172\/JCI114931","volume":"86","author":"T Naveh-Many","year":"1990","unstructured":"Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest. 1990;86(6):1968\u201375.","journal-title":"J Clin Invest"},{"issue":"3","key":"365_CR24","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.kint.2016.04.024","volume":"90","author":"NA Dhayat","year":"2016","unstructured":"Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, Leichtle AB, Paccaud F, Mohaupt M, Fiedler GM, Devuyst O, Pech\u00e8re-Bertschi A, Burnier M, Martin PY, Bochud M, Vogt B, Fuster DG. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function. Kidney Int. 2016;90(3):648\u201357.","journal-title":"Kidney Int"},{"issue":"2","key":"365_CR25","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1681\/ASN.2016090944","volume":"28","author":"T Naveh-Many","year":"2016","unstructured":"Naveh-Many T, Silver J. The Pas de Trois of Vitamin D, FGF23, and PTH. J Am Soc Nephrol. 2016;28(2):393\u20135.","journal-title":"J Am Soc Nephrol"},{"issue":"20","key":"365_CR26","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342(20):1478\u201383.","journal-title":"N Engl J Med"},{"issue":"4","key":"365_CR27","first-page":"303","volume":"24","author":"KA Hruska","year":"2015","unstructured":"Hruska KA, Seifert M, Sugatani T. Pathophysiology of the chronic kidney disease-mineral bone disorder. Curr Opin Nephrol Hypertens. 2015;24(4):303\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"8","key":"365_CR28","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1681\/ASN.2013080818","volume":"25","author":"Y Fang","year":"2014","unstructured":"Fang Y, Ginsberg C, Seifert M, Agapova O, Sugatani T, Register TC, Freedman BI, Monier-Faugere MC, Malluche H, Hruska KA. CKD-induced wingless\/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder. J Am Soc Nephrol. 2014;25(8):1760\u201373.","journal-title":"J Am Soc Nephrol"},{"key":"365_CR29","first-page":"S1","volume":"53","author":"National Kidney Foundation K\/DOQI Workgroup","year":"2009","unstructured":"National Kidney Foundation K\/DOQI Workgroup. K\/DOQI clinical practice guidelines for nutrition in children with chronic kidney disease. Am J Kidney Dis. 2009;53:S1\u2013123.","journal-title":"Am J Kidney Dis"},{"key":"365_CR30","first-page":"S1","volume":"46","author":"National Kidney Foundation K\/DOQI Workgroup","year":"2005","unstructured":"National Kidney Foundation K\/DOQI Workgroup. K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis. 2005;46:S1\u2013121.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"365_CR31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/ki.2012.403","volume":"83","author":"KM Hill","year":"2013","unstructured":"Hill KM, Martin BR, Wastney ME, McCabe GP, Moe SM, Weaver CM, Peacock M. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int. 2013;83(5):959\u201366.","journal-title":"Kidney Int"},{"issue":"4","key":"365_CR32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","volume":"33","author":"AJ Bleyer","year":"1999","unstructured":"Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33(4):694\u2013701.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"365_CR33","doi-asserted-by":"crossref","first-page":"e0156891","DOI":"10.1371\/journal.pone.0156891","volume":"11","author":"N Sekercioglu","year":"2016","unstructured":"Sekercioglu N, Thabane L, D\u00edaz Mart\u00ednez JP, Nesrallah G, Longo CJ, Busse JW, Akhtar-Danesh N, Agarwal A, Al-Khalifah R, Iorio A, Guyatt GH. Comparative effectiveness of phosphate binders in patients with chronic kidney disease: a systematic review and network meta-analysis. PLoS One. 2016;11(6):e0156891.","journal-title":"PLoS One"},{"issue":"4","key":"365_CR34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1525-139X.2007.00299.x","volume":"20","author":"TB Dr\u00fceke","year":"2007","unstructured":"Dr\u00fceke TB. Lanthanum carbonate as a first-line phosphate binder: the \u201ccons\u201d. Semin Dial. 2007;20(4):329\u201332.","journal-title":"Semin Dial"},{"issue":"2","key":"365_CR35","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1681\/ASN.2014020212","volume":"26","author":"JB Lewis","year":"2015","unstructured":"Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP, Collaborative Study Group. Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol. 2015;26(2):493\u2013503.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"365_CR36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1681\/ASN.2011121213","volume":"23","author":"SC Schiavi","year":"2012","unstructured":"Schiavi SC, Tang W, Bracken C, O'Brien SP, Song W, Boulanger J, Ryan S, Phillips L, Liu S, Arbeeny C, Ledbetter S, Sabbagh Y. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012;23(10):1691\u2013700.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"365_CR37","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04211007","volume":"3","author":"SC Cheng","year":"2008","unstructured":"Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008;3(4):1131\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"365_CR38","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00467-015-3208-1","volume":"31","author":"R El Borolossy","year":"2016","unstructured":"El Borolossy R, El Wakeel LM, El Hakim I, Sabri N. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol. 2016;31(2):289\u201396.","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"365_CR39","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000362424","volume":"39","author":"M Rao","year":"2014","unstructured":"Rao M, Steffes M, Bostom A, Ix JH. Effect of niacin on FGF23 concentration in chronic kidney disease. Am J Nephrol. 2014;39(6):484\u201390.","journal-title":"Am J Nephrol"},{"issue":"10","key":"365_CR40","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1681\/ASN.2015020117","volume":"26","author":"T Isakova","year":"2015","unstructured":"Isakova T, Ix JH, Sprague SM, Raphael KL, Fried L, Gassman JJ, Raj D, Cheung AK, Kusek JW, Flessner MF, Wolf M, Block GA. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol. 2015;26(10):2328\u201339.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"365_CR41","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ki.2010.316","volume":"78","author":"D Borzych","year":"2010","unstructured":"Borzych D, Rees L, Ha IS, Chua A, Valles PG, Lipka M, Zambrano P, Ahlenstiel T, Bakkaloglu SA, Spizzirri AP, Lopez L, Ozaltin F, Printza N, Hari P, Klaus G, Bak M, Vogel A, Ariceta G, Yap HK, Warady BA, Schaefer F, International Pediatric PD Network (IPPN). The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int. 2010;78(12):1295\u2013304.","journal-title":"Kidney Int"},{"issue":"1","key":"365_CR42","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1046\/j.1523-1755.2003.00727.x","volume":"63","author":"JW Groothoff","year":"2003","unstructured":"Groothoff JW, Offringa M, Van Eck-Smit BL, Gruppen MP, Van De Kar NJ, Wolff ED, Lilien MR, Davin JC, Heymans HS, Dekker FW. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int. 2003;63(1):266\u201375.","journal-title":"Kidney Int"},{"issue":"6","key":"365_CR43","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1359\/jbmr.080220","volume":"23","author":"H Wang","year":"2008","unstructured":"Wang H, Yoshiko Y, Yamamoto R, Minamizaki T, Kozai K, Tanne K, Aubin JE, Maeda N. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J Bone Miner Res. 2008;23(6):939\u201348.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"365_CR44","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s00223-011-9501-5","volume":"89","author":"V Shalhoub","year":"2011","unstructured":"Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, Hawkins N, Richards WG. Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int. 2011;89(2):140\u201350.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"365_CR45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Guti\u00e9rrez","year":"2008","unstructured":"\u2022\u2022 Guti\u00e9rrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, J\u00fcppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584\u201392. This study demonstrates that elevated FGF23 levels are independently associated with mortality in CKD patients","journal-title":"N Engl J Med"},{"issue":"23","key":"365_CR46","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"\u2022\u2022 Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Guti\u00e9rrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011;305(23):2432\u20139. This study demonstrates that elevated FGF23 levels are independently associated with progression to ESRD and mortality in CKD patients","journal-title":"JAMA"},{"issue":"26","key":"365_CR47","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","unstructured":"Trial Investigators EVOLVE, Chertow GM, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482\u201394.","journal-title":"N Engl J Med"},{"issue":"1","key":"365_CR48","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Dr\u00fceke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015;132(1):27\u201339.","journal-title":"Circulation"},{"issue":"10","key":"365_CR49","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s00467-008-0810-5","volume":"23","author":"J Muscheites","year":"2008","unstructured":"Muscheites J, Wigger M, Drueckler E, Fischer DC, Kundt G, Haffner D. Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr Nephrol. 2008;23(10):1823\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"10","key":"365_CR50","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1007\/s00467-012-2186-9","volume":"27","author":"D Padhi","year":"2012","unstructured":"Padhi D, Langman CB, Fathallah-Shaykh S, Warady BA, Salusky IB, Lee E, Wang C, Posvar E. An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol. 2012;27(10):1953\u20139.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"365_CR51","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2215\/CJN.04760511","volume":"7","author":"R Shroff","year":"2012","unstructured":"Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C, Wells D, Aitkenhead H, Manickavasagar B, van't Hoff W, Rees L. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol. 2012;7(2):216\u201323.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"365_CR52","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1093\/ndt\/gfw081","volume":"31","author":"C Zoccali","year":"2016","unstructured":"Zoccali C, Mallamaci F. Moderator\u2019s view: vitamin D deficiency treatment in advanced chronic kidney disease: a close look at the emperor\u2019s clothes. Nephrol Dial Transplant. 2016;31(5):714\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"365_CR53","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"\u2022\u2022 Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Guti\u00e9rrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393\u2013408. This study demonstrates that FGF23 directly induces left ventricular hypertrophy in an animal model","journal-title":"J Clin Invest"},{"issue":"9","key":"365_CR54","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, MMKD Study Group, Kuen E, K\u00f6nig P, Kraatz G, Mann JF, M\u00fcller GA, K\u00f6hler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007;18(9):2600\u20138.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"365_CR55","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.2215\/CJN.02110216","volume":"11","author":"AA Portale","year":"2016","unstructured":"Portale AA, Wolf MS, Messinger S, Perwad F, J\u00fcppner H, Warady BA, Furth SL, Salusky IB. Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol. 2016;11(11):1989\u201398.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"365_CR56","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.13281211","volume":"7","author":"J Munoz Mendoza","year":"2012","unstructured":"Munoz Mendoza J, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, Bazzano LA, Xie D, Kretzler M, Nessel L, Hamm LL, Negrea L, Leonard MB, Raj D, Wolf M, Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol. 2012;7(7):1155\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"365_CR57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ki.2015.290","volume":"89","author":"V David","year":"2016","unstructured":"David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 2016;89(1):135\u201346.","journal-title":"Kidney Int"},{"issue":"46","key":"365_CR58","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","volume":"108","author":"EG Farrow","year":"2011","unstructured":"Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108(46):E1146\u201355.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"365_CR59","doi-asserted-by":"crossref","first-page":"F1369","DOI":"10.1152\/ajprenal.00281.2016","volume":"311","author":"MR Hanudel","year":"2016","unstructured":"Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol. 2016;311(6):F1369\u201377.","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-017-0365-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-017-0365-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T12:48:02Z","timestamp":1601988482000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-017-0365-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["365"],"URL":"https:\/\/doi.org\/10.1007\/s11914-017-0365-0","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]}}}